Document O1Ymeb3ZYM5depGwYJn3z474p

DownloadSearchable PDFRandom document
Inspection Date(s): BROOKLYN CANCER CENTER INSPECTION REPORT 19 September 2023 Inspection Announced: Yes Facility or Site Name: Facility/Site Physical Location: (city, state, zip code) Mailing address (if different from above): Facility/Site Contacts: Website: Brooklyn Cancer Center 86 Fleet Place Fort Greene/Downtown Brooklyn, NY 11201 Frankie Goldsberry, Director Environmental Services fgoldsberry@tbh.org 718-250-8887 | Mobile: 646-285-3498 Jasmine Ip, CHSP, CHCM, Senior Director, Health and Safety jip@tbh.org Phone: 718-250-8535 | Mobile: 929-359-0142 https://www.tbh.org/service/brooklyn-cancer-center https://brooklyncancer.com/ RCRA ID Number: NYD041555665 Latitude, Longitude: 40.69039533563467, -73.97797172046127 Facility/Site Personnel Participating in Inspection: Frankie Goldsberry Director Environmental Services Jasmine Ip Senior Director, Health and Safety Chris Guerra Environmental Records Alyssa Amonte Nurse Manager Mark Tartakovsky Pharmacist Inspector(s): Carl F. Plssl US EPA, Enforcement Officer/Engineer Additional Inspection Report Elements: Photos Inspection Report Author: Carl F. Plssl CARL PLOSSL Digitally signed by CARL PLOSSL Date: 2023.11.27 15:38:42 -05'00' Plossl.Carl@epa.gov (212) 637-4088 Supervisor Leonard Grossman LEONARD GROSSMAN Digitally signed by LEONARD GROSSMAN Date: 2023.11.27 15:46:38 -05'00' 1 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT SECTION I - INTRODUCTION Purpose of the Inspection Objective A Compliance Evaluation Inspection (CEI) was conducted to determine the facility's compliance with the Resource Conservation and Recovery Act (RCRA) requirements for hazardous waste management. The facility had never been inspected for RCRA compliance and had no notification history. Opening Conference I, EPA Region 2 RCRA inspector Plssl, arrived at the main entrance to the Brooklyn Hospital facilities at ~10:13 am on September 19, 2023, for an announced inspection of the hospital. A previous inspection in June was cut short as the Senior Director of Health and Safety was on vacation. I announced and identified myself at the reception desk, contacted Mr. Goldsberry, Director Environmental Services, and was subsequently met by him. Ms. Ip, Senior Director, Health & Safety, joined us and we discussed the facility past and current operations, waste management and disposal practices, and the nature of federal RCRA inspections. Approximately 11:36 am, we arrived at the Brooklyn Cancer Center, which occupied the ground floor of the multi-use building. I was introduced to Mr. Guerra, Inventory Controller, Ms. Amonte, Nurse Manager, and Mr. Tartakovsky, Pharmacist, during our walkthrough. Facility/Site Description From Brooklyn Cancer Center: The Brooklyn Cancer Center (TBCC) was established through a partnership between New York Cancer & Blood Specialists (NYCBS), one of the leading oncology practices in the nation, and The Brooklyn Hospital Center (TBHC), an independent community hospital. Residents of Brooklyn no longer need to travel out of the borough for excellent cancer care. In Downtown Brooklyn, TBCC proudly offers compassionate cancer care close to home. At TBCC, our patients receive personalized treatment plans from a diverse team of specialists who use the most advanced cancer treatments, innovative therapies, clinical trials, and support services. We care for every patient like family, providing affordable and convenient care and the best patient experience possible. Ensuring the health and well-being of our patients is and always will be our first priority. According to Mr. Goldsberry and Ms. Ip: General 2 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT o Main Campus, Cancer Center, and Dialysis Center are all Brooklyn Hospital Facilities Cancer Center o Cancer Center proper (including patient treatment) o Storage areas o Pharmacology Hazardous wastes regularly generated: o Chemotherapy drugs, both residual and out-of-date o Universal wastes Waste dispositions: o Waste accumulation containers: Yellow Bin- medical waste and empty and "trace" medication containers Red Bin- sharps Black Bin- out-of-date medication/containers o Black Bin waste container contents, capacity 17-gal, are taken by a staff nurse to Pharmacology for management (~every 1-2 days o Waste chemo drugs, including black bin contents, stored in negative pressure room until transport/disposal o Waste chemo were not managed as hazardous waste Note: wastes can be hazardous waste because of their characteristics (ignitability, corrosivity, reactivity and toxicity) or because they are specifically listed as hazardous waste. Records requested: o At least one year's worth of chemo waste disposal records o See Appendices SECTION II - OBSERVATIONS The accompanying Brooklyn Cancer Center Inspection Photos.pptx document is the complete set of inspection observations made during the facility walkthrough with Mr. Goldsberry and Ms. Ip. SECTION III - AREAS OF CONCERN Concerns Disposal of waste chemotherapy drugs as medical waste (no hazardous waste manifest waste) No determination of hazardous waste generator status (i.e., conditionally-exempt of small quantity or large quantity generator) Hazardous waste training may not extend to all staff that manage chemo wastes Closing Conference 3 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT Mr. Goldsberry, Ms. Ip, and I reviewed my findings and we discussed any follow up. Ms. Ip provided several follow up emails (see Appendix 3). Ms. Ip responded the same day with: Please see the attached: o Cancer Center Chemo Drug Inventory List o The annual required training for all hospital staff on hazardous material and emergency management o We will work on providing additional training for lab personnel Further information was provided by Ms. Ip on 20 September 2023: Additionally, after getting clarification from our Medical Waste company, Stericycle, we only put the Yellow Bins (chemo waste) in the Regulated Medical Waste (RMW)cardboard boxes. RMW is treated as hazardous waste. Further information was provided by Ms. Ip on 5 October 2023: In addition to the emails I sent you on 9/19 and 9/20, attached is the DOT Hazardous materials certifications for certain staff at the Cancer Center and the Lab who handle with chemical and/or hazardous waste. As mentioned in my previous email, all hospital staff are required to take the annual general awareness training on hazardous material and emergency management. Please feel free to reach out if you need additional information. INSPECTION PHOTOGRAPHS: See Brooklyn Cancer Center Inspection Photos.pptx FOLLOW UP EMAILS: See Appendix 1 CHEMO DRUG INVENTORY: See Appendix 2 4 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT Appendix 1: Follow Up Emails From: Jasmine Ip <jip@tbh.org> Sent: Thursday, October 5, 2023 2:47 PM To: Plossl, Carl Cc: Goldsberry, Frankie; Wong, Paul; Almitra Taylor Subject: RE: The Brooklyn Hospital Center - EPA Inspection Attachments: The Brooklyn Hospital Center - EPA Inspection; Re: The Brooklyn Hospital Center - EPA Inspection; Laboratory Dept. - DOT Hazardous Materials Training Certs.pdf; Cancer Center Employees - DOT Hazardous Materials Training Certs..pdf Caution: This email originated from outside EPA, please exercise additional caution when deciding whether to open attachments or click on provided links. Hi Carl, In addition to the emails I sent you on 9/19 and 9/20, attached is the DOT Hazardous materials certifications for certain staff at the Cancer Center and the Lab who handle with chemical and/or hazardous waste. As mentioned in my previous email, all hospital staff are required to take the annual general awareness training on hazardous material and emergency management. Please feel free to reach out if you need additional information. Thank you Jasmine Jasmine Ip, CHSP, CHCM Senior Director, Health and Safety The Brooklyn Hospital Center | 121 DeKalb Avenue, Brooklyn, NY Phone: 718-250-8535 | Mobile: 929-359-0142 Email: jip@tbh.org 11201 From: Jasmine Ip <jip@tbh.org> Sent: Wednesday, September 20, 2023 12:40 PM To: Plossl.Carl@epa.gov Cc: Goldsberry, Frankie <fgoldsberry@tbh.org> Subject: Re: The Brooklyn Hospital Center - EPA Inspection Hi Carl, 5 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT Additionally, after getting clarification from our Medical Waste company, Stericycle, we only put the Yellow Bins (chemo waste) in the Regulated Medical Waste (RMW)cardboard boxes. RMW is treated as hazardous waste. Please see attached photos. 6 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT Thanks Jasmine On Sep 19, 2023, at 3:09PM, Jasmine Ip <jip@tbh.org> wrote: Hi Carl, Please see the attached: 1. Cancer Center Chemo Drug Inventory List 2. The annual required training for all hospital staff on hazardous material and emergency management 1. We will work on providing additional training for lab personnel Thank you 7 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT Jasmine Ip, CHSP, CHCM Senior Director, Health and Safety The Brooklyn Hospital Center | 121 DeKalb Avenue, Brooklyn, NY Phone: 718-250-8535 | Mobile: 929-359-0142 Email: jip@tbh.org <image001.jpg> 11201 <Cancer Center Inventory 2022.xlsx> <course-4-2-environment-of-care-hazardous-materials-emergencymanagement9bb6yH3k.docx> This electronic message is intended to be for the use only of the named recipient, and may contain information that is confidential or privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the contents of this message is strictly prohibited. If you have received this message in error or are not the named recipient(s), please notify us immediately by contacting the sender at the electronic mail address noted above, and delete and destroy all copies of this message. Thank you. TBHC_DISC 8 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT Appendix 2: Chemo Drug Inventory Service Locati LocDesc Item NDC UPC ProductDescription No on 051059 101 Hazardous 36418 68817013 3688171345 ABRAXANE 100MG Room 75 450 00 051059 101 Hazardous 36418 68817013 3688171345 ABRAXANE 100MG Room 75 450 00 051059 101 Hazardous 55824 00780883 3007808836 ADAKVEO 10MG/ML 10ML PF Room 81 61 10 SPD 051059 101 Hazardous 45150 51144005 0511440500 ADCETRIS 50MG DSHP SPD Room 11 001 17 051059 101 Hazardous 35496 00027623 3000276230 ALIMTA 500MG SUV Room 23 01 16 051059 101 Hazardous 37460 55513002 3555130280 ARANESP SJCT 200MCG 0.4 Room 62 801 11 PSORB 051059 101 Hazardous 45676 50242006 3502420610 AVASTIN 25MG/ML 16ML SPD Room 32 101 18 051059 101 Hazardous 41525 63323013 3633231372 BLEOMYCIN 30USP UNITS Room 42 720 05 051059 101 Hazardous 54737 71288010 1037128810 BLEOMYCIN 30USP UNITS PF Room 56 720 7208 051059 101 Hazardous 57966 71288011 3712881181 BORTEZOMIB 3.5MG PF IV/SQ Room 85 810 08 051059 101 Hazardous 57994 01439098 3014390980 BORTEZOMIB 3.5MG SQ/IV Room 08 01 10 051059 101 Hazardous 57976 43598042 3435984266 BORTEZOMIB 3.5MGPF IV/SQ Room 42 660 00 051059 101 Hazardous 43597 00097529 3000975290 CAMPTOSAR 20MG/ML 5ML Room 33 03 34 CYTSF 051059 101 Hazardous 56866 55150033 3551503350 CARBOPLATIN 10MG/ML Room 47 501 15 45ML 051059 101 Hazardous 56866 55150033 3551503350 CARBOPLATIN 10MG/ML Room 47 501 15 45ML 051059 101 Hazardous 56866 55150033 3551503350 CARBOPLATIN 10MG/ML Room 47 501 15 45ML 051059 101 Hazardous 53105 16729028 3167292883 CISPLATIN 1MG/ML 100ML Room 29 838 85 051059 101 Hazardous 57018 70860021 3708602180 CYCLOPHOSPHAMIDE Room 91 803 38 200MG/ML 2.5M 051059 101 Hazardous 57018 70860021 3708602180 CYCLOPHOSPHAMIDE Room 83 805 52 200MG/ML 5ML 051059 101 Hazardous 49824 00027669 3000276690 CYRAMZA 10MG/ML 10ML Room 19 01 14 SPD 051059 101 Hazardous 49824 00027678 3000276780 CYRAMZA 10MG/ML 50ML Room 35 01 16 SPD 051059 101 Hazardous 29103 63323012 3633231271 DACARBAZINE 100MG 10 Room 62 710 07 051059 101 Hazardous 29103 63323012 3633231271 DACARBAZINE 100MG 10 Room 62 710 07 051059 101 Hazardous 29103 63323012 3633231271 DACARBAZINE 100MG 10 Room 62 710 07 051059 101 Hazardous 29103 63323012 3633231282 DACARBAZINE 200MG 10 Room 88 820 03 FormC ode VIAL VIAL VIAL VIAL VIAL SYRING E VIAL VIAL VIAL VL SDV SDV VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL Strength 100MG 100MG 10MG/ML 50MG 500MG 200MCG/0.4 ML 25MG/ML 30U 30U 3.5MG 3.5MG 3.5MG 20MG/ML 10MG/ML 10MG/ML 10MG/ML 1MG/ML 200MG/ML 200MG/ML 10MG/ML 10MG/ML 100MG 100MG 100MG 200MG 9 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT Hazardous 51919 57894050 3578945022 DARZALEX 20MG/ML 20ML VIAL Room 94 220 03 SPD Hazardous 51919 57894050 3578945020 DARZALEX 20MG/ML 5ML SPD VIAL Room 11 205 50 Hazardous 56447 57894050 3578945030 DARZALEX FSPR120-2000 VIAL Room 11 301 19 15ML SPD Hazardous 36868 63323051 3633235161 DEXAMT SOD PH 10MG/ML VIAL Room 05 610 09 10X10ML Hazardous 33860 63323066 3633236640 DIPHENHYD 50MG/ML VIAL Room 67 401 15 25X1ML Hazardous 53139 45963076 3459637655 DOCETAXEL 20MG/ML 4ML VIAL Room 45 552 29 Hazardous 55622 03380063 3033800630 DOXIL 2MG/ML 10ML VIAL Room 10 01 17 Hazardous 48455 47335005 3473350504 DOXORUB LIP 2MG/ML 25ML VIAL Room 09 040 00 Hazardous 44591 00693031 3006930312 DOXORUBICIN 2MG/ML 10ML VIAL Room 03 20 07 Hazardous 44590 00693030 3006930302 DOXORUBICIN 2MG/ML 5ML VIAL Room 79 20 00 Hazardous 50575 45963073 3459637335 DOXORUBICIN HCL 2MG/ML VIAL Room 75 357 73 10ML Hazardous 50575 45963073 3459637335 DOXORUBICIN HCL 2MG/ML VIAL Room 75 357 73 10ML Hazardous 57320 01439085 3014390850 DOXORUBICIN HCL 2MG/ML VIAL Room 11 01 10 10ML Hazardous 57320 01439086 3014390860 DOXORUBICIN HCL 2MG/ML VIAL Room 37 01 17 25ML Hazardous 50584 45963073 3459637335 DOXORUBICIN HCL 2MG/ML VIAL Room 33 355 59 5ML FTV Hazardous 57324 01439092 3014390920 DOXORUBICIN HCL 50MG VIAL Room 58 01 18 Hazardous 49892 64764030 3647643002 ENTYVIO 300MG PF SPD VIAL Room 16 020 03 Hazardous 43564 66733095 3667339582 ERBITUX 2MG/ML 100ML VIAL Room 99 823 31 Hazardous 43883 16729011 3167291143 ETOPOSIDE 20MG/ML 5ML VIAL Room 36 431 18 Hazardous 43883 16729011 3167291143 ETOPOSIDE 20MG/ML 5ML VIAL Room 36 431 18 Hazardous 49721 67457043 3674574332 FAMOTIDINE 10MG/ML VIAL Room 62 322 26 25X2ML Hazardous 52846 25021021 3250212159 FLUOROURACIL 50MG/ML VIAL Room 33 599 99 100ML Hazardous 28349 63323011 3633231171 FLUOROURACIL 50MG/ML VIAL Room 27 710 08 10X10ML Hazardous 28349 63323011 3633231175 FLUOROURACIL 50MG/ML VIAL Room 43 751 11 50ML Hazardous 52846 25021021 3250212159 FLUOROURACIL 50MG/ML VIAL Room 25 598 82 50ML Hazardous 49341 50242007 3502420700 GAZYVA 25MG/ML 40ML SPD VIAL Room 21 001 10 Hazardous 55077 71288011 3712881145 GEMCITABINE 1GM SDV PF VIAL Room 02 450 06 10 20MG/ML 20MG/ML 120MG2000U/ML 10MG/ML 50MG/ML 20MG/ML 2MG/ML 2MG/ML 2MG/ML 2MG/ML 2MG/ML 2MG/ML 2MG/ML 2MG/ML 2MG/ML 10MG 300MG 2MG/ML 20MG/ML 20MG/ML 10MG/ML 50MG/ML 50MG/ML 50MG/ML 50MG/ML 25MG/ML 1GM 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT Hazardous 50476 25021023 3250212355 GEMCITABINE 1GM SUV PF VIAL Room 18 550 08 Hazardous 55076 71288011 3712881131 GEMCITABINE 200MG SDV PF VIAL Room 94 310 03 Hazardous 50476 25021023 3250212341 GEMCITABINE 200MG SUV PF VIAL Room 34 410 05 Hazardous 51031 18657011 3186571170 HYLENEX 150U/ML 4X1ML VIAL Room 06 704 41 Hazardous 53571 03104611 3031046115 IMFINZI 50MG/ML 10ML SPD VIAL Room 73 50 00 Hazardous 53571 03104500 3031045001 IMFINZI 50MG/ML 2.4ML SPD VIAL Room 81 12 25 Hazardous 54216 60505612 3605056128 IRINOTECAN HCL 20MG/ML VIAL Room 15 800 02 2ML Hazardous 54216 60505612 3605056128 IRINOTECAN HCL 20MG/ML VIAL Room 23 801 19 5ML Hazardous 48316 50242008 3502420870 KADCYLA 160MG SPD VIAL Room 08 701 18 Hazardous 55550 00063026 3000630260 KEYTRUDA 25MG/ML 2X4ML VIAL Room 08 04 48 SPD Hazardous 54811 75987008 3608098010 KRYSTEXXA 8MG/ML1ML VIAL Room 48 010 18 W/DIL SPD Hazardous 54742 76075010 3760751030 KYPROLIS 10MG SPD VIAL Room 67 301 15 Hazardous 52622 76075010 3760751010 KYPROLIS 60MG SPD VIAL Room 33 101 11 Hazardous 53710 01439554 3014395540 LEUCOVORIN 100MG VIAL Room 83 01 11 Hazardous 55021 67457053 3674575303 LEUCOVORIN 350MG VIAL Room 66 035 52 Hazardous 52789 01439552 3014395520 LEUCOVORIN 350MG PF VIAL Room 73 01 17 Hazardous 54701 25021082 3250218285 LEUCOVORIN 500MG PF VIAL Room 09 850 02 Hazardous 54701 25021082 3250218285 LEUCOVORIN 500MG PF VIAL Room 09 850 02 Hazardous 55555 67457052 3674575281 LEUCOVORIN CALC 100MG PF VIAL Room 29 810 06 Hazardous 55555 67457052 3674575292 LEUCOVORIN CALC 200MG PF VIAL Room 37 920 02 Hazardous 55555 67457052 3674575292 LEUCOVORIN CALC 200MG PF VIAL Room 37 920 02 Hazardous 29355 63323071 3633237110 LEUCOVORIN CALCIUM VIAL Room 67 100 09 500MG Hazardous 54216 63323006 2036332306 MAGNESIUM SULF 50% VIAL Room 31 403 4031 25X2ML Hazardous 55513 55513020 3555132070 MVASI 25MG/ML 16ML VIAL Room 38 701 10 Hazardous 55513 55513020 3555132060 MVASI 25MG/ML 4ML VIAL Room 20 601 13 Hazardous 55825 55513022 3555132230 NPLATE 125MCG PF SPD VIAL Room 56 301 10 Hazardous 52867 55513022 3555132210 NPLATE 250MCG PF SPD VIAL Room 37 101 16 11 1GM 200MG 200MG 150U/ML 50MG/ML 50MG/ML 20MG/ML 20MG/ML 160MG 25MG/ML 8MG/ML 10MG 60MG 100MG 350MG 350MG 500MG 500MG 100MG 200MG 200MG 500MG 50% 25MG/ML 25MG/ML 125MCG 250MCG 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 BROOKLYN Hazardous 52867 Room 52 Hazardous 52867 Room 52 Hazardous 55801 Room 21 Hazardous 57450 Room 05 Hazardous 50476 Room 00 Hazardous 50475 Room 84 Hazardous 50475 Room 84 Hazardous 47287 Room 05 Hazardous 50129 Room 50 Hazardous 54357 Room 30 Hazardous 42236 Room 16 Hazardous 56527 Room 48 Hazardous 53759 Room 85 Hazardous 35659 Room 67 Hazardous 57744 Room 43 Hazardous 45986 Room 60 Hazardous 55230 Room 97 Hazardous 57275 Room 32 Hazardous 57275 Room 40 Hazardous 28080 Room 61 Hazardous 45674 Room 67 Hazardous 45674 Room 75 Hazardous 55972 Room 81 Hazardous 55972 Room 99 Hazardous 11658 Room 10 Hazardous 52911 Room 33 Hazardous 42841 Room 54 RCRA Compliance Branch CANCER CENTER INSPECTION REPORT 55513022 3555132220 NPLATE 500MCG PF SPD 201 13 55513022 3555132220 NPLATE 500MCG PF SPD 201 13 67457084 3674578474 OGIVRI 420MG PF 744 43 78206014 3782061480 ONTRUZANT 420MG W/DIL 801 18 MDV 00033774 3000337741 OPDIVO 10MG/ML 10ML SPD 12 22 00033772 3000337721 OPDIVO 10MG/ML 4ML SPD 11 11 00033772 3000337721 OPDIVO 10MG/ML 4ML SPD 11 11 07033985 3070339850 OXALIPLATIN 5MG/ML 10ML 01 15 67457046 3674574691 OXALIPLATIN 5MG/ML 10ML 910 02 PF 71288010 3712881012 OXALIPLATIN 5MG/ML 20ML 120 09 61703036 3617033632 OXALIPLATIN 5MG/ML 20ML 322 20 72266016 3722661620 OXALIPLATIN 5MG/ML 20ML 201 14 PF 70860020 3708602005 PACLITAXEL 6MG/ML 50ML 050 07 61703034 3617033425 PACLITAXEL 6MG/ML 50ML 250 08 42367053 3423675313 PEMFEXY 25MG/ML 20ML 133 30 50242014 3502421450 PERJETA 30MG/ML 14ML SPD 501 15 09907075 3030990707 POTASSIUM CL 20MEQ 26 5267 24X100ML LF 59572071 3595727110 REBLOZYL 25MG SPD 101 13 59572077 3595727750 REBLOZYL 75MG SPD 501 15 57894003 3578940300 REMICADE 100MG 001 10 50242005 3502420512 RITUXAN 10MG/ML 10ML SPD 121 17 50242005 3502420530 RITUXAN 10MG/ML 50ML SPD 306 68 00690238 3006902380 RUXIENCE 10MG/ML 10ML 01 12 00690249 3006902490 RUXIENCE 10MG/ML 50ML 01 18 63323018 2036332318 SODIUM CL 0.9% 25X10ML UU 610 6108 57894005 3579840542 STELARA 5MG/ML 26ML SPD 427 76 57894006 3578940610 STELARA 90MG/ML 103 38 12 VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL INJ VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL VIAL SYRING E 500MCG 500MCG 420MG 420MG 10MG/ML 10MG/ML 10MG/ML 5MG/ML 5MG/ML 5MG/ML 5MG/ML 5MG/ML 6MG/ML 6MG/ML 25MG/20ML 30MG/ML 20MEQ/100 ML 25MG 75MG 100MG 10MG/ML 10MG/ML 10MG/ML 10MG/ML 0.9% 5MG/ML 90MG/ML 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 051059 101 RCRA Compliance Branch BROOKLYN CANCER CENTER INSPECTION REPORT Hazardous 55221 50242091 3502429180 TECENTRIQ 60MG/ML 14ML VIAL Room 31 801 15 SPD Hazardous 52507 50242091 3502429170 TECENTRIQ 60MG/ML 20ML VIAL Room 33 701 18 SPD Hazardous 55073 55135013 3551351320 TRODELVY 180MG SDV VIAL Room 14 201 11 Hazardous 55805 63459010 3634591031 TRUXIMA 10MG/ML 10ML VIAL Room 84 310 05 Hazardous 55805 63459010 3634591045 TRUXIMA 10MG/ML 50ML VIAL Room 92 450 08 Hazardous 38051 55513095 3555139560 VECTIBIX 20MG/ML 20ML VIAL Room 99 601 17 Hazardous 38051 55513095 3555139540 VECTIBIX 20MG/ML 5ML VIAL Room 73 401 13 Hazardous 42264 59572010 3595721020 VIDAZA 100MG SUV PF SPD VIAL Room 45 201 19 Hazardous 14329 63323027 3633232781 VINBLASTINE 1MG/ML 10ML VIAL Room 39 810 06 Hazardous 24143 61703030 3617033090 VINCRISTINE 1MG/ML 1ML VIAL Room 08 906 68 Hazardous 24143 61703030 3617033091 VINCRISTINE 1MG/ML 2ML VIAL Room 16 916 67 Hazardous 11659 63323018 3633231851 WATER 25X10ML STR INJ VIAL Room 27 510 07 Hazardous 12942 04094887 3040948875 WATER 25X50ML STR INJ VIAL Room 06 50 00 Hazardous 12942 04094887 3040948875 WATER 25X50ML STR INJ VIAL Room 06 50 00 Hazardous 45223 00032327 3000323271 YERVOY 5MG/ML 10ML SPD VIAL Room 14 11 14 Hazardous 56543 68727071 3687277120 ZEPZELCA 4MG SDV PF SPD VIAL Room 06 201 10 60MG/ML 60MG/ML 180MG 10MG/ML 10MG/ML 20MG/ML 20MG/ML 100MG 1MG/ML 1MG/ML 1MG/ML 5MG/ML 4MG 13